Skip to the line map
Before the Needle

Which Stem Cell Therapies Are FDA-Approved in the United States?

  • Updated November 14, 2026
  • Stop 1 of 4 on the FDA status and safety line

The FDA does not approve “stem cell therapy” as a category. It licenses specific products for specific diseases and patient groups. As of November 14, 2026, the approved stem-cell-based products fall into three groups: blood stem cell (hematopoietic progenitor cell) transplant products, most of them cord blood products plus OMISIRGE and TREGZI; a small number of genetically modified blood stem cell products for named inherited disorders; and one mesenchymal stromal cell product, Ryoncil, for a pediatric transplant complication. None is approved as an injection for arthritis, tendon pain or back pain.

What does “FDA-approved” mean for a cell therapy?

An approval is a license for one product, made one way, for the uses written in its label. The label names the disease, the patient population (often with an age limit), and the conditions of use. Everything outside that label is not covered by the approval, even if the same cell type is involved.

That is why the useful question is never “Is stem cell therapy approved?” It is “Is this product, under this name, approved for this condition in someone like me?” Approval of one product says nothing about a different product that uses similar cells, and approval for one disease says nothing about another disease.

Approved examples and their exact indications

The list below was checked against FDA’s Approved Cellular and Gene Therapy Products directory and the individual product pages on November 14, 2026. The directory describes itself as a list of licensed products from FDA’s Office of Therapeutic Products; on that day it showed “Content current as of 10/30/2026” and listed 55 products. Most of those 55 are not stem cell products at all: they include CAR-T cancer therapies, viral gene therapies and engineered skin or tissue products. Only the groups below involve stem or stromal cells.

Cord blood hematopoietic progenitor cell (HPC) products. The directory lists nine licensed cord blood products: ALLOCORD, CLEVECORD, Ducord, HEMACORD, REGENECYTE, and HPC, Cord Blood from Clinimmune Labs, MD Anderson Cord Blood Bank, LifeSouth and Bloodworks. Their labeled use is narrow. The HEMACORD page, for example, describes use in unrelated-donor blood stem cell transplants, together with a preparative regimen, to rebuild the blood and immune system in people with inherited, acquired or treatment-related disorders of blood production.

Other blood stem cell transplant products. OMISIRGE (omidubicel-onlv) is labeled for people 12 and older with blood cancers who are planned for cord blood transplantation after myeloablative conditioning, and for people 6 and older with severe aplastic anemia after reduced-intensity conditioning. TREGZI, with an approval letter dated July 1, 2026, contains hematopoietic stem and progenitor cells together with T cells and is labeled for adults with hematological malignancies (blood cancers) undergoing matched-donor blood stem cell transplantation with a myeloablative preparative regimen.

The mesenchymal stromal cell product. Ryoncil (remestemcel-L-rknd) was announced by FDA on December 18, 2024 as the first approved mesenchymal stromal cell therapy. Its indication is steroid-refractory acute graft-versus-host disease in pediatric patients 2 months of age and older. Graft-versus-host disease is an immune complication that can follow a donor blood stem cell transplant. It is not a joint, spine or tendon condition.

Genetically modified autologous blood stem cell products. These are made from a patient’s own blood stem cells that are modified in a manufacturing facility and returned. They are listed separately here because they are gene therapies, and each has its own narrow label:

Product Labeled condition Labeled population
CASGEVY Sickle cell disease with recurrent vaso-occlusive crises; transfusion-dependent beta-thalassemia 2 years and older under the most recent license listed by FDA
LYFGENIA Sickle cell disease with a history of vaso-occlusive events 12 years and older
ZYNTEGLO Beta-thalassemia requiring regular red blood cell transfusions Adults and children
SKYSONA Early, active cerebral adrenoleukodystrophy without an HLA-matched donor Boys 4 to 17 years
LENMELDY Specified early forms of metachromatic leukodystrophy Children
KRESLADI Severe leukocyte adhesion deficiency-I without an HLA-matched sibling donor Children
WASKYRA Wiskott-Aldrich syndrome with a mutation in the WAS gene, when blood stem cell transplantation is appropriate and no suitable HLA-matched related donor is available 6 months and older, including adults

None of these is an orthopedic approval. No row covers injection into a joint, disc or tendon.

The product pages for CASGEVY, LYFGENIA, ZYNTEGLO, SKYSONA, LENMELDY, KRESLADI and WASKYRA on FDA’s site carry the exact label wording and the dated approval letters. KRESLADI’s letter is dated March 26, 2026 and WASKYRA’s December 9, 2025, so a list written before those dates will be incomplete.

Why doesn’t approval for one disease transfer to joint injections?

Because the approval covers the indication, not the cell type. Ryoncil is the clearest example. It is a mesenchymal stromal cell product, and “mesenchymal stem cell” injections are marketed for knees and backs. The shared vocabulary does not move the approval. Ryoncil’s license covers children with a specific transplant complication; it does not cover adults with osteoarthritis, and it does not cover a different company’s cells prepared in a different way.

The same logic applies to cord blood. FDA’s consumer alert on regenerative medicine products lists orthopedic conditions such as osteoarthritis, tendonitis, disc disease and back, knee or shoulder pain among the uses these products have not been approved for. A 2018 outbreak of infections after injections of an unapproved cord-blood-derived product, described in our article on the risks of unapproved stem cell injections, happened in exactly that gap.

Be careful with older references. FDA’s 2020 consumer alert and its patient information page, both showing content dated April 2024, say the only approved stem cell products are cord blood products. That statement did not cover the genetically modified blood stem cell products: CASGEVY and LYFGENIA, for example, were approved on December 8, 2023, before those pages’ content date. Ryoncil’s December 2024 approval and the later approvals added more. Neither page works as a current inventory; the directory and the individual product pages do.

Which labels do NOT mean FDA product approval?

Four phrases are often presented as if they were approval. An FDA-registered establishment has filed its facility and product listing with FDA; registration is not a review of whether the product works. An Investigational New Drug (IND) application allows a product to be studied in humans under FDA oversight; it is not permission to sell it as treatment. A listing on ClinicalTrials.gov means a study was registered, nothing more. And “361 HCT/P” refers to a narrow regulatory category for certain minimally processed tissues used for their normal function; it does not mean FDA reviewed a clinic’s injection for a disease. Exosome products have their own status question, covered in whether exosome injections are FDA-approved. For a step-by-step way to test a clinic’s claims, see how to check a stem cell clinic’s evidence.

How to verify an advertised product

  1. Write down the exact product name the provider uses, not the category. “Our stem cell injection” is not a product name.
  2. Search for that name in FDA’s Approved Cellular and Gene Therapy Products directory.
  3. If it appears, open its page and read the indication. Compare the disease, age group and conditions of use with your own situation.
  4. If it does not appear, treat the approval claim as unconfirmed rather than settled, and ask the provider for the product’s FDA approval letter and prescribing information (the label), which an approved product has. Also ask whether the product is being given under an IND as part of a clinical study, and ask for the IND number and the FDA communication acknowledging it. FDA’s patient guidance suggests confirming this with your own clinician.
  5. Note the date you checked. The directory changes as new products are licensed.

Status block: what to recheck

The product list and indications above reflect FDA pages read on November 14, 2026. Before relying on any entry, open the current FDA product page, because labels are updated and new products are added.

Is an FDA-registered stem cell clinic FDA-approved? No. Registration describes a facility’s filing with FDA, not a product approval or an endorsement of the clinic’s treatments.

Are stem cell injections for knee arthritis approved? No product in the FDA directory checked on November 14, 2026 carries an indication for knee osteoarthritis injections.

Every stop on the FDA status and safety line

  1. Which Stem Cell Therapies Are FDA-Approved in the United States?
  2. Are Exosome Injections FDA-Approved in the United States?
  3. What Are the Risks of Unapproved Stem Cell Injections?
  4. How to Check Whether a Stem Cell Clinic’s Claims Are Supported by Evidence

Reader comments

Leave a note on this stop

Your email address will not be published. Required fields are marked *